Recombinant interferon-Beta-1 a plus ribavirin for the treatment of chronic HCV infection: A prospective, randomized, comparative pilot study

Sang Hoon Ahn, Hyun Woong Lee, Yong Soo Kim, Ja Kyung Kim, Kwang Hyub Han, Chae Yoon Chon, Young Myoung Moon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-/3 (IFN-/3-1a) plus oral ribavirin versus interferon alpha (IFN-a) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naive patients were randomized into two equal-sized treatment groups. Both IFN-/3-1a (44g) and IFN-a (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-/3-1a group and IFN-a groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-/3-1a group than in the IFN-a group, and there were more HCV genotype 1 patients in the IFN-/3-1a group (eight versus seven). The IFN-/3-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-/3-1a and ribavirin and that of IFN-α and ribavirin. (Gut and Liver 2009;3:20-25).

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalGut and liver
Volume3
Issue number1
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Ribavirin
Interferon-beta
Infection
Therapeutics
Safety
Chronic Hepatitis C
Virus Diseases
Interferon beta-1a
Viral Load
Interferon-alpha
Antiviral Agents
Genotype
Observation
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Ahn, Sang Hoon ; Lee, Hyun Woong ; Kim, Yong Soo ; Kim, Ja Kyung ; Han, Kwang Hyub ; Chon, Chae Yoon ; Moon, Young Myoung. / Recombinant interferon-Beta-1 a plus ribavirin for the treatment of chronic HCV infection : A prospective, randomized, comparative pilot study. In: Gut and liver. 2009 ; Vol. 3, No. 1. pp. 20-25.
@article{cb6c779604f5436bbf60d948de2ea202,
title = "Recombinant interferon-Beta-1 a plus ribavirin for the treatment of chronic HCV infection: A prospective, randomized, comparative pilot study",
abstract = "Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-/3 (IFN-/3-1a) plus oral ribavirin versus interferon alpha (IFN-a) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naive patients were randomized into two equal-sized treatment groups. Both IFN-/3-1a (44g) and IFN-a (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60{\%}) and four patients (40{\%}) in the IFN-/3-1a group and IFN-a groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40{\%}). However, the baseline viral load was significantly higher (p=0.034) in the IFN-/3-1a group than in the IFN-a group, and there were more HCV genotype 1 patients in the IFN-/3-1a group (eight versus seven). The IFN-/3-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-/3-1a and ribavirin and that of IFN-α and ribavirin. (Gut and Liver 2009;3:20-25).",
author = "Ahn, {Sang Hoon} and Lee, {Hyun Woong} and Kim, {Yong Soo} and Kim, {Ja Kyung} and Han, {Kwang Hyub} and Chon, {Chae Yoon} and Moon, {Young Myoung}",
year = "2009",
month = "3",
day = "1",
doi = "10.5009/gnl.2009.3.1.20",
language = "English",
volume = "3",
pages = "20--25",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

Recombinant interferon-Beta-1 a plus ribavirin for the treatment of chronic HCV infection : A prospective, randomized, comparative pilot study. / Ahn, Sang Hoon; Lee, Hyun Woong; Kim, Yong Soo; Kim, Ja Kyung; Han, Kwang Hyub; Chon, Chae Yoon; Moon, Young Myoung.

In: Gut and liver, Vol. 3, No. 1, 01.03.2009, p. 20-25.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recombinant interferon-Beta-1 a plus ribavirin for the treatment of chronic HCV infection

T2 - A prospective, randomized, comparative pilot study

AU - Ahn, Sang Hoon

AU - Lee, Hyun Woong

AU - Kim, Yong Soo

AU - Kim, Ja Kyung

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

AU - Moon, Young Myoung

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-/3 (IFN-/3-1a) plus oral ribavirin versus interferon alpha (IFN-a) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naive patients were randomized into two equal-sized treatment groups. Both IFN-/3-1a (44g) and IFN-a (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-/3-1a group and IFN-a groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-/3-1a group than in the IFN-a group, and there were more HCV genotype 1 patients in the IFN-/3-1a group (eight versus seven). The IFN-/3-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-/3-1a and ribavirin and that of IFN-α and ribavirin. (Gut and Liver 2009;3:20-25).

AB - Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-/3 (IFN-/3-1a) plus oral ribavirin versus interferon alpha (IFN-a) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naive patients were randomized into two equal-sized treatment groups. Both IFN-/3-1a (44g) and IFN-a (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-/3-1a group and IFN-a groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-/3-1a group than in the IFN-a group, and there were more HCV genotype 1 patients in the IFN-/3-1a group (eight versus seven). The IFN-/3-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-/3-1a and ribavirin and that of IFN-α and ribavirin. (Gut and Liver 2009;3:20-25).

UR - http://www.scopus.com/inward/record.url?scp=67249144306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67249144306&partnerID=8YFLogxK

U2 - 10.5009/gnl.2009.3.1.20

DO - 10.5009/gnl.2009.3.1.20

M3 - Article

C2 - 20479896

AN - SCOPUS:67249144306

VL - 3

SP - 20

EP - 25

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -